Zepbound KwikPen launches through LillyDirect at $299 a month

Eli Lilly said on Feb. 23, 2026 that the FDA approved a label expansion for Zepbound (tirzepatide) covering a four-dose KwikPen that delivers a full month of treatment in one device. Self-pay patients can now get all doses of the drug in a KwikPen or in single-dose vials at the same price, starting at $299 a month for the 2.5 mg dose ^[1][2][4].

Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist. It is a different molecule from semaglutide, the ingredient in Ozempic, Wegovy and Rybelsus ^[1].

The KwikPen will be sold in all six Zepbound doses — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — Reuters reported ^[2]. The same device is already used to deliver Mounjaro, Lilly's tirzepatide product for type 2 diabetes, and it is sold in the United Kingdom, Australia, the Middle East and Canada ^[2]. In the United States, Zepbound, approved by the FDA in 2023, has also been available as a single-dose autoinjector and as vials ^[2].

Lilly said the pen is available by prescription now through LillyDirect, its direct-to-patient pharmacy channel ^[1]. The company said more than 1 million patients accessed Lilly treatments through LillyDirect in 2025, and that one out of every three new patients starting a branded weight management medication was prescribed Zepbound self-pay vials that year ^[1]. Lilly cited IQVIA data in calling Zepbound the most prescribed weight management medication of 2025 ^[1]. Reuters reported that Zepbound has overtaken Novo Nordisk's Wegovy as the U.S. weight-loss market leader based on prescription data ^[2].

On price, Lilly said its self-pay pricing is 50 percent or more below the list price of other incretin (GLP-1) obesity medicines ^[1]. A separate consumer pricing guide lists Zepbound self-pay at $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg through 15 mg, with a requirement to refill within 45 days at maintenance doses, and says the program cannot be combined with commercial insurance, Medicare or Medicaid ^[3]. That guide lists the undiscounted retail list price at $1,086 a month ^[3]. Lilly's own release states only the starting price ^[1][2].

Lilly pointed to two trials in announcing the launch. In SURMOUNT-1, adults taking Zepbound 15 mg lost an average of 20.9 percent of body weight over 72 weeks, compared with 3.1 percent on placebo ^[1]. In the open-label SURMOUNT-5 study, people taking Zepbound lost an average of 50 lbs (20.2 percent) versus 33 lbs (13.7 percent) on injectable Wegovy; Lilly notes that open-label data are less certain and that factors beyond the studied medications may have contributed to weight loss ^[1].

"As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities ^[1].

Why it matters for patients

Self-pay patients who prefer a pen over a vial and syringe now have that option at the same price Lilly charges for vials, rather than paying more for a different delivery format ^[1].

Dose labels matter here. The 2.5 mg strength is a starting dose and not an approved maintenance dose; Lilly lists 5 mg, 10 mg and 15 mg as the recommended maintenance doses for weight reduction, and 10 mg or 15 mg for obstructive sleep apnea ^[1].

The self-pay channel is separate from insurance. The $299-to-$449 pricing described in the consumer guide applies to people paying cash through LillyDirect and cannot be combined with commercial insurance, Medicare or Medicaid ^[3]. That guide also says no income-based patient assistance program exists for Zepbound, while the Lilly Cares Foundation program covers Mounjaro for type 2 diabetes only ^[3].

Medicare coverage is changing during 2026. Part D covers Zepbound for obstructive sleep apnea, and the consumer guide says the CMS Medicare GLP-1 Bridge demonstration program extends coverage to Zepbound's KwikPen for an obesity-only diagnosis at a $50 monthly copay starting July 1, 2026 ^[3].

Patients who use the pen should not share it with anyone else, even if the needle has been changed, according to the prescribing information ^[1][4].

It has not been reported whether the KwikPen will be stocked at retail pharmacies or covered under commercial insurance formularies, or whether the vials will remain available in the same doses and at the same prices over time.

What happens next

The dated milestones described in the pricing guide are July 1, 2026, when the CMS Medicare GLP-1 Bridge program is set to begin for Zepbound's KwikPen for obesity, running through Dec. 31, 2027, and Dec. 31, 2026, when the Zepbound savings card for commercially insured patients is listed as expiring ^[3].